919 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
Bayer and Teva Double Down on Worst M&A Deals of Decade http://www.gurufocus.com/news/995213/bayer-and-teva-double-down-on-worst-ma-deals-of-decade Dec 04, 2019 - Bayer and Teva Double Down on Worst M&A Deals of Decade, Stocks: BAYN,TEVA,GILD,MRK,NVS,BMY,PFE,GSK,SHRS,SNY,AMGN,A, release date:Dec 03, 2019
J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders http://www.zacks.com/stock/news/653885/jjs-jnj-new-tests-reveal-no-asbestos-in-baby-powders?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-653885 Dec 04, 2019 - J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
Why The Bear Attack On Teva Pharmaceutical Must End https://seekingalpha.com/article/4309342-bear-attack-teva-pharmaceutical-must-end?source=feed_tag_israel Nov 26, 2019 - Renewed bearishness on Teva over the opioid subpoena may prove short-lived.Third-quarter results a positive inflection point.Business recovery underway.
Why The Bear Attack On Teva Pharmaceutical Must End https://seekingalpha.com/article/4309342-why-bear-attack-on-teva-pharmaceutical-must-end?source=feed_tag_israel Nov 26, 2019 - Renewed bearishness on Teva over the opioid subpoena may prove short-lived.Third-quarter results a positive inflection point.Business recovery underway.
Generic Drugmakers Gain as Price-Fixing Probe Nears an End http://www.zacks.com/stock/news/641354/generic-drugmakers-gain-as-price-fixing-probe-nears-an-end?cid=CS-ZC-FT-analyst_blog|investment_ideas-641354 Nov 26, 2019 - Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.
Teva in talks with DoJ to end generics probe - Bloomberg https://seekingalpha.com/news/3521819-teva-talks-doj-end-generics-probe-bloomberg?source=feed_news_all Nov 25, 2019 - Teva Pharmaceuticals (TEVA +6.5%) pops higher in morning trade following a Bloomberg report that it has held talks with the U.S. Department of Justice about resolving a criminal antitrust probe of all
Teva inks early-stage drug research deals https://seekingalpha.com/news/3521812-teva-inks-early-stage-drug-research-deals?source=feed_news_all Nov 25, 2019 - Teva (NYSE:TEVA) is starting the week up 5.6% after signing research agreements with two leading Israeli academic institutes to boost its early-stage drug development.A partnership with Tel Aviv Unive
Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA http://www.zacks.com/stock/news/631469/endos-endp-bla-for-cellulite-treatment-accepted-by-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-631469 Nov 21, 2019 - The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.
Teva Is Due For A Substantial Re-Rating https://seekingalpha.com/article/4308148-teva-due-substantial-re-rating?source=feed_tag_israel Nov 20, 2019 - Thanks to its debt offering, a heavily dilutive equity issuance has become very unlikely.The upsized offering also highlights that debt markets are not seeing a large bankruptcy risk.The only remainin
Teva Is Due For A Substantial Re-Rating https://seekingalpha.com/article/4308148-teva-is-due-for-substantial-re-rating?source=feed_tag_israel Nov 20, 2019 -

Pages: 123456...92

Page 1>